Cyclacel pharmaceuticals, inc. (CYCCP)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Operating activities:
Net loss

-1,220

-2,305

-1,900

-1,783

-1,842

-2,018

-2,069

-1,852

-1,349

-1,871

-1,857

-2,187

-1,555

-2,839

-2,946

-2,965

-3,041

-3,374

-2,709

-3,347

-4,912

-4,799

-4,907

-4,812

-4,869

Adjustments to reconcile net loss to net cash used in operating activities:
Change in valuation of financial instruments associated with stock purchase agreement

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

27

4

20

227

4

64

47

Depreciation

5

5

5

4

6

7

7

8

7

7

8

8

9

24

34

33

42

53

55

50

52

-

-

-

-

Gain on disposal of property and equipment

-

9

0

0

29

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

69

23

23

Stock-based compensation

91

105

183

93

85

76

88

86

81

66

65

66

69

168

194

199

221

281

141

159

164

634

219

183

187

Changes in lease liability

-10

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Prepaid expenses and other assets

874

-890

-73

-466

1,215

647

-1,180

-16

876

232

-718

-1,883

1,137

190

383

-1,194

182

241

615

-2,309

1,111

858

876

-1,394

1,360

Accounts payable and other current liabilities

-799

207

-363

-1,363

-689

546

71

-61

-2

-190

-183

29

-1,196

-94

148

503

-187

605

-1,005

-1,953

887

1,069

-716

-933

1,246

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-3,810

-2,943

-2,953

-1,036

-3,147

-2,676

-4,106

-2,778

-4,900

-3,668

-6,207

-4,101

-4,726

Net cash used in operating activities

-2,807

-1,117

-2,011

-2,635

-3,684

-2,036

-723

-1,803

-2,139

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Investing activities:
Purchase of property, plant and equipment

4

3

4

1

2

6

2

9

22

2

9

0

2

-

-

-

-

2

10

8

14

7

237

34

31

Proceeds from sale of property and equipment

-

9

0

0

29

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Minimum royalty payments received from termination of ALIGN license agreement

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-73

0

0

-23

-96

-96

-96

-96

Net cash used in investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-2

-

-

-

-

71

-10

-8

9

89

-141

62

65

Net cash provided by (used in) investing activities

-4

6

-4

-1

27

-6

-2

-9

-22

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Financing activities:
Proceeds from issuing common stock, net of issuance costs (Payments of issuance costs)

-

0

-7

-50

4,106

-

-

-

-

-2

13,688

977

86

-

-

-

-

485

220

-77

10,433

1,456

0

9,289

1,676

Payment of preferred stock dividend

50

50

50

51

50

50

50

51

50

50

50

51

50

50

50

50

50

51

50

50

50

50

50

50

50

Net cash provided by (used in) financing activities

-50

-50

-57

-101

4,056

580

-50

-51

-50

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Effect of exchange rate changes on cash and cash equivalents

-101

-

-

-

31

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net (decrease) in cash and cash equivalents

-2,962

-

-

-

430

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by / (used in) financing activities

-

-

-

-

-

-

-

-

-

-

-

-

36

1,503

5,037

104

-50

434

170

-127

10,383

1,385

-50

9,239

1,626

Effect of exchange rate changes on cash and cash equivalents

-

-

-

-

-

-

-

-38

26

-41

54

137

-15

-78

14

-252

-128

-117

-228

452

-318

-324

-351

102

43

Net (decrease) in cash and cash equivalents

-

-

-

-

-

-

-

-1,901

-2,185

-2,115

12,434

862

-3,791

-1,509

2,098

-1,184

-3,325

-2,288

-4,174

-2,461

5,174

-

-

-

-

Net decrease in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-6,749

5,302

-2,992

Supplemental cash flow information:
Interest

-

-

-

-

-

-

-

84

69

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash received during the period for: Interest

28

-

-

-

79

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1

1

2

2

1

Lease liability

-

-

-

-

-1,505

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Right-of-use asset

-

-

-

-

1,385

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest

-

-

-

-

-

-

-

-

-

-

-

-

12

-

10

11

10

-

-

-

-

-

-

-

-

Taxes

-

-

-

-

-

-

-

0

0

0

0

1,807

8

-

-

-

-

-

-

-

-

-

0

1,786

25

Non cash financing activities:
Accrual of preferred stock dividends

50

0

0

0

50

0

0

0

50

0

0

0

50

0

0

0

50

0

0

0

50

-

-

-

-